Effects of Intracoronary Low-Dose Recombinant Tissue Plasminogen Activator as an Adjunct to Primary PCI in Patients with STEMI and Large Thrombus Burden: A Randomized, Double-Blind, Placebo-Controlled Trial

<p>Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: </p><ul><li>Consultant Fee/Honoraria/Speaker’s Bureau - J&J; Novartis</li><li>Grant Support/Research Contract - Abbott; Amgen</li><li>DMC - Merck/Schering Plough</li></ul>